Insulet/PODD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Insulet

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.

Ticker

PODD

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

James Hollingshead

Employees

3,000

Headquarters

Acton, United States

Insulet Metrics

BasicAdvanced
$12B
Market cap
55.16
P/E ratio
$3.21
EPS
1.14
Beta
-
Dividend rate
$12B
1.14305
$298.95
$125.82
866K
3.743
2.747
172.328
177.248
61.775
65.58%
9.53%
36.18%
11.42%
55.163
6.969
15.691
19.376
90.785
30.17%
122,233.80%
23.34%
205.61%

What the Analysts think about Insulet

Analyst Ratings

Majority rating from 23 analysts.
Buy

Insulet Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
11.65% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$442M
-13.36%
Net income
$52M
-50.15%
Profit margin
11.65%
-42.50%

Insulet Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 87.90%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.38
$0.71
$1.40
$0.73
-
Expected
$0.26
$0.40
$0.66
$0.39
$0.56
Surprise
44.52%
76.54%
112.99%
87.90%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Insulet stock?

Insulet (PODD) has a market cap of $12B as of June 19, 2024.

What is the P/E ratio for Insulet stock?

The price to earnings (P/E) ratio for Insulet (PODD) stock is 55.16 as of June 19, 2024.

Does Insulet stock pay dividends?

No, Insulet (PODD) stock does not pay dividends to its shareholders as of June 19, 2024.

When is the next Insulet dividend payment date?

Insulet (PODD) stock does not pay dividends to its shareholders.

What is the beta indicator for Insulet?

Insulet (PODD) has a beta rating of 1.14. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Insulet stock price target?

The target price for Insulet (PODD) stock is $233.07, which is NaN% below the current price of $. This is an average based on projections from 20 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Insulet stock

Buy or sell Insulet stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing